黄芩苷治疗非酒精性脂肪性肝炎大鼠抗炎的疗效  

Anti-inflammation effect of baicalin on rat models of nonalcoholic steatohepatitis

作　　者：艾正琳[1] 洪珊 胡居龙[1] 李坪[1] 周玉玲[1] 梁秀霞[1] 姚树坤[2] AI Zhenglin;HONG Shan;HU Julong;LI Ping;ZHOU Yuling;LIANG Xiuxia;YAO Shukun(Department of Gastroenterology,Beijing Ditan Hospital, Capital Medical University,Beijing 100015,China;Department of Gastroenterology,China-Japan Friendship Hospital, Ministry of Health,Beijing 100029,China)

机构地区：[1]首都医科大学附属北京地坛医院消化内科,北京100015 [2]卫生部中日友好医院消化内科,北京100029

出　　处：《山东大学学报（医学版）》2019年第7期55-60,共6页Journal of Shandong University:Health Sciences

摘　　要：目的观察黄芩苷对非酒精性脂肪性肝炎(NASH)的治疗效果及其抗炎疗效。方法采用高脂饮食诱导建立大鼠NASH模型,给予不同剂量的黄芩苷(15、30、60 mg/kg·d)治疗后,测定大鼠肝质量及体质量变化,苏木精-伊红(HE)染色观察肝组织病理学变化,并测定血清丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)水平,比色法测定肝组织超氧化物歧化酶(SOD)、还原型谷胱甘肽(GSH)酶活性及丙二醛(MDA)含量变化,酶联免疫吸附(ELASA)测定肝组织肿瘤坏死因子α(TNFα)、白介素-6(IL-6)、白介素-1β(IL-1β)含量变化。结果经黄芩苷治疗后,NASH大鼠的体质量及肝质量减轻(F=1609.79,P<0.001;F=155.17,P<0.001),二指标随剂量增加而下降。经不同剂量黄芩苷治疗后,病理学可见肝细胞脂肪变性逐渐减轻,小叶间炎性细胞浸润逐渐减少。治疗后,血清ALT和AST减少(F=177.16,P<0.001;F=2 998.11,P<0.001),随剂量增加而减少。而肝脏GSH、SOD酶活性经黄芩苷治疗后增加(F=398.47,P<0.001;F=256.07,P<0.001),随治疗浓度增加而增加。肝组织MDA的变化则相反(F=237.98,P<0.001),随治疗浓度增加而下降。肝组织TNFα、IL-1β、IL-6含量经黄芩苷治疗后均降低(F=399.15,P<0.001;F=314.76,P<0.001;F=108.38,P<0.001),三者随治疗浓度增加而下降。结论黄芩苷能减轻NASH大鼠的脂肪变性程度,通过增加GSH、SOD酶的活性,减少TNFα、IL-1β、IL-6炎性因子的产生,缓解肝脏的炎症,发挥其抗炎作用。Objective To investigate the efficacy of baicalin in the treatment of non-alcoholic steatohepatitis(NASH) in rat models and the anti-inflammatory effect. Methods After NASH rat models were induced, they were intragastrically given different doses of baicalin 15, 30, 60 mg/(kg·d). The body weight and liver weight were measured. The histopathology changes in hepatic steatosis were observed with hematoxylin-eosin(HE) staining. The serum alanine amiotransferase(ALT) and aspartate aminotransferase(AST) levels were assessed. The changes of hepatic reduced glutathione hormone(GSH), superoxide dismutase(SOD) and hepatic malondialdehyde(MDA) were detected with spectrophotometry. The levels of tumor necrosis factor α(TNFα), interleukin 6(IL-6) and interleukin 1β(IL-1β) in liver tissues were measured with enzyme linked immunosorbent assay(ELASA). Results After baicalin treatment, the body weight and liver weight of NASH rats were significantly reduced(F=1 609.79, P<0.001;F=155.17, P<0.001)in a dose-dependent manner. The steatosis of hepatic cells gradually decreased, and the infiltration of inflammatory cells was relieved. The serum ALT and AST reduced(F=177.16, P<0.001;F=2 998.11, P<0.001), the activity of GSH and SOD increased(F=398.47, P<0.001;F=256.07, P<0.001);the MDA;TNFα, IL-1β and IL-6 levels decreased(F=237.98, P<0.001;F=399.15, P<0.001;F=314.76, P<0.001;F=108.38, P<0.001), in a dose-dependent manner. Conclusion Baicalin can alleviate the degree of steatosis and inflammation in NASH rats. By increasing the activity of GSH and SOD enzymes, and reducing the levels of TNFα, IL-1β and IL-6, it exerts anti-inflammatory effects and alleviates liver inflammation.

关 键 词：黄芩苷 抗炎 非酒精性脂肪性肝炎 肿瘤坏死因子Α 白介素 

分 类 号：R575.1[医药卫生—消化系统]